Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.303,67
-0,04%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Dicerna Pharmaceuticals Inc (DRNA) Dicerna Pharmaceuticals Inc (DRNA) Notizie

DRNA

Dicerna Pharmaceuticals (DRNA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DRNA
DataOraFonteTitoloSimboloCompagnia
14/02/202212:18Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
10/01/202223:00Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:DRNADicerna Pharmaceuticals Inc
03/01/202212:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:DRNADicerna Pharmaceuticals Inc
29/12/202122:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117:18Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117:15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117:06Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202116:52Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202116:47Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115:35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115:04Business WireNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionNASDAQ:DRNADicerna Pharmaceuticals Inc
25/12/202114:00Business WireDicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
09/12/202114:41PR Newswire (US)Direxion Launches mRNA ETF (MSGR)NASDAQ:DRNADicerna Pharmaceuticals Inc
09/12/202100:55TipRanksDicerna Pharma (DRNA) Gets a Hold Rating from Chardan CapitalNASDAQ:DRNADicerna Pharmaceuticals Inc
25/11/202110:09TipRanksLeerink Partners Keeps a Buy Rating on Dicerna Pharma (DRNA)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202123:07Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202122:58Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:DRNADicerna Pharmaceuticals Inc
19/11/202113:16TipRanksDicerna Soars 78.7% on Novo Nordisk’s $3.3B Acquisition OfferNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202123:32Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202123:08Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202117:47Dow Jones NewsDicerna Shares Soar on Takeover by Novo NordiskNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202113:51Dow Jones NewsNovo Nordisk to Buy Dicerna for $38.25 a ShareNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202113:00Business WireNovo Nordisk to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114:54Dow Jones NewsDicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of PrincipleNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114:10Business WireDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114:00Business WireDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202113:50Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202113:30Business WireDicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateNASDAQ:DRNADicerna Pharmaceuticals Inc
04/11/202118:15Business Wire Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DRNA

La tua Cronologia

BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
TRN
Terna Trasmissione Elett...
BIT
LDO
Leonardo
BIT
SRG
Snam
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
BIT
TEN
Tenaris
BIT
A2A
A2A
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network